Monogram Orthopaedics (MGRM) to Release Earnings on Wednesday

Monogram Orthopaedics (NASDAQ:MGRM - Get Free Report) is anticipated to announce its Q4 2024 earnings results after the market closes on Wednesday, March 12th. Analysts expect the company to announce earnings of ($0.11) per share for the quarter.

Monogram Orthopaedics (NASDAQ:MGRM - Get Free Report) last announced its earnings results on Wednesday, March 12th. The company reported ($0.08) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.11) by $0.03. On average, analysts expect Monogram Orthopaedics to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Monogram Orthopaedics Price Performance

NASDAQ MGRM traded up $0.05 during trading on Wednesday, hitting $2.32. The company's stock had a trading volume of 42,960 shares, compared to its average volume of 143,225. Monogram Orthopaedics has a fifty-two week low of $1.53 and a fifty-two week high of $4.90. The company has a market cap of $79.60 million, a PE ratio of -4.94 and a beta of 1.66. The business's 50 day simple moving average is $2.54 and its 200-day simple moving average is $2.50.

Analyst Upgrades and Downgrades

A number of analysts recently commented on MGRM shares. Roth Mkm started coverage on shares of Monogram Orthopaedics in a research note on Monday, December 9th. They issued a "buy" rating and a $4.00 target price for the company. Roth Capital upgraded shares of Monogram Orthopaedics to a "strong-buy" rating in a research note on Monday, December 9th.

About Monogram Orthopaedics

Monogram Orthopaedics, Inc focuses on developing a product solution architecture to enable patient-optimized orthopaedic implants. The company intends to produce and market robotic surgical equipment and related software, orthopedic implants, tissue ablation tools, navigation consumables, and other miscellaneous instrumentation for use in reconstructive joint replacement procedures.